[EATG Global HIV News daily digest] Digest #30-2010

[EATG Global HIV News daily digest]

Global HIV News Daily Digest

Copied as fair use  -  Ana  -





Latest Headlines




  Drug firms apply brand to generics 
  Pharma Industry Thursday 18 February 2010
					
  
Some prestigious brand-name pharmaceutical companies that once looked
askance at the high-volume, low-cost business of generic drugs are now
becoming major purveyors of generic medicines.
  SOURCE:
The New York Times




  Biotech marathon: Vaccines and open innovation, but less IP? 
  Pharma Industry Wednesday 17 February 2010
					
  
Intellectual property seems to be at a crossroads where industry still
strongly favours it but some speakers voiced concerns about the
possible counter-effects of too much IP protection on innovation.
  SOURCE:
Intellectual Property Watch




  Canada on AIDS: empty promises, broken lives 
  World Policy Wednesday 17 February 2010
					
  
We call on the Canadian government to ensure that HIV/AIDS remains a
central topic for discussion and action at the next G8/G20 meetings.
The world has an obligation and moral duty to fulfill the pledge to
fund universal access to modern and effective HIV.
  SOURCE:
The Hill Times




  HIV drug resistance lasts about 1 year in women treated with nevirapine to prevent infant infection
  Treatment Wednesday 17 February 2010
					
  
The increased risk of failure could only be detected in women who began
full HIV treatment within about a year after receiving sdNVP.
  SOURCE:
EurekAlert!




  Phase III study: GARDASIL prevents 77.5% of pre-cursor lesions to anal cancer
  HIV & STIs Wednesday 17 February 2010
					
  
In a new phase III study, GARDASIL prevented 77.5 per cent of anal
intraepithelial neoplasia associated with human papillomavirus types 6,
11, 16 and 18 in 16-to-26 year-old men who have sex with men. 
  SOURCE:
The Medical News




  Achillion
announces positive 96-week data for elvucitabine at the 17th Annual
Conference on Retroviruses and Opportunistic Infections
  Treatment Wednesday 17 February 2010
					
  
Elvucitabine is an L-cytosine nucleoside analog reverse transcriptase
inhibitor (NRTI) that has previously demonstrated potent in vitro
antiviral activity against HIV, including strains resistant to other
NRTIs. 
  SOURCE:
Achillion Pharmaceuticals, Inc.




  CROI: PEPFAR to give bigger boost to local healthcare
  World Policy Wednesday 17 February 2010
					
  
The next focus for the President's Emergency Plan for AIDS Relief
should be bolstering the overall healthcare systems in the developing
countries it serves.
  SOURCE:
MedPage Today




  Goosby warns of need for long-term funding commitment for AIDS, says financial trades tax is 'interesting' 
  World Policy Wednesday 17 February 2010
					
  
International donors need to start looking at a 30 to 40 year time
frame for 'long-term sustainable support' to manage the global response
to AIDS.
  SOURCE:
Aidsmap


----------------------------------------------------
DISCLAIMER
The articles in this digest represent a diversity of opinions on topics
of interest to the HIV treatment activist community. The EATG is not
responsible for their content. The articles posted in this digest do
not necessarily reflect EATG views or opinions.
FAIR USE NOTICE
The digest may contain copyrighted material which has not always been
specifically authorised by the copyright owner. Such material is made
available for educational purposes to advance the understanding of
scientific, ethical, legal and social issues. It is believed that this
constitutes a 'fair use' of any such copyrighted material. This
material is distributed without profit.


 

Information in this digest was accurately quoted during its compilation.




      
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://mail.eatg.org/pipermail/eatg-forum_eatg.org/attachments/20100217/290d236b/attachment.html>